Integra LifeSciences Holdings has purchased Johnson and Johnson’s (J&J) Codman Neurosurgery business for $1.045bn.
The acquisition will strengthen the US-based surgical and medical instrument manufacturer’s neurosurgical products portfolio.
The Israeli non-invasive Ffr measurements developer plans to use the funds to carry out global trials for 510K Food and Drug Administration (FDA) approval.
Mallinckrodt plc has signed a licensing agreement to develop US-based pharmaceutical company NeuroproteXeon Inc’s pharmaceutical-grade xenon gas inhalation therapy.
The UK-based pharmaceutical company will pay $10m towards initial development costs as per the agreement and obtain an exclusive license to market the therapy. It will make additional payments of up to $25m once it has achieved certain clinical and sales milestones.
US-based company AxoGen Inc plans to raise up to $92.24m by issuing four million shares of its common stock priced at $18.98 a share.
The Canadian robotic solutions designer will use the funds to develop innovative products and carry out research to improve its production efficiency.